India Pharma Outlook Team | Tuesday, 26 May 2026
.jpeg "Patent Exclusivity Expiry Recalibrating India's Pharma Logistics")
As we traverse through 2026 and by the time we reach 2030, pharmaceutical products accounting for an estimated $200–300+ billion in annual global sales are expected to lose patent exclusivity - often referred to as the “patent cliff” or “super cliff.”
These include major therapies across oncology, diabetes, immunology, and obesity, creating a once-in-a-decade opportunity for global generic manufacturers.
Examples of high-impact molecules:
As India places itself as the world’s largest supplier of generic medicines, generic manufacturers in India can legally produce cheaper versions when patent lapses. This directly results in the explosion in the production volumes which in turn will create significant opportunities for Pharma logistics service providers. Richard Saynor recently emphasized that once pricing barriers fall after patent expiry, demand can become difficult to predict because affordability dramatically expands patient access, but supply readiness becomes the bigger challenge.
Furthermore, as the top-three supplier by value, India has positioned itself among the greatest beneficiaries. Currently, the country accounts for about 20 percent of global generic drug exports while roughly supplying 40 percent of the generics consumed in the US. At the same time, India is the largest supplier of medicines to Sub-Saharan Africa.
Unlike the previous patent cliff cycle dominated by simple oral solids, the upcoming wave increasingly involves complex generics, specialty injectables, biologics and biosimilars. This materially raises the bar for logistics providers, since these therapies often require highly controlled cold-chain integrity, stricter regulatory documentation, and real-time environmental monitoring.
Also Read: Pharmaceutical Procurement Strategies: How to Optimize Costs
India’s pharmaceutical logistics sector must prepare to surf this trend, wherein, companies across the cold chain, freight forwarding, and warehousing segments must readily invest in temperature-controlled transportation infrastructure, innovative tracking and monitoring systems, and regulatory-compliant distribution networks capable of meeting the stringent standards of US FDA, the European Medicines Agency, and the WHO.
Pharmaceutical-grade logistics requires specific temperature windows across the entire journey from manufacturing plant to dispensary. This is often 2 to 8 degrees Celsius for biologics and vaccines, or 15 to 25 degrees for standard solid-dose medicines.
So, any lapse in the cold chain directly results in product degradation, rejection at border inspections, or recalls. Hence, the margin for error is narrowing day by day as India ramps up exports of complex molecules, biosimilars, and specialty generics triggered by patent expirations.
The air cargo is the preferred mode for high-value, time-sensitive pharma shipments. And as the pharmaceutical exports increase, we will witness significant pressure on air cargo capacity as well as on the dedicated pharmaceutical logistics hubs at major airports and seaports.
To mitigate this pressure, India’s air cargo infrastructure hubs like Mumbai, Delhi, Hyderabad, and Bengaluru must expand to absorb increased pharmaceutical freight volumes.
Port-based logistics will also be critical. Sea freight accounts for a large portion of bulk pharmaceutical raw material (API) imports into India and is increasingly being used for finished goods exports to markets like Africa and Southeast Asia where cost sensitivity is higher. Dedicated pharmaceutical berths, bonded warehouses, and faster customs clearance mechanisms at major ports can make a material difference to supply chain efficiency.
Important Industry stakeholders state that to successfully capitalize the patent cliff opportunity, it will require close collaboration between pharmaceutical manufacturers, contract development and manufacturing organisations (CDMOs), logistics technology providers and freight operators.
Adding to this, digital platforms which can offer end-to-end supply chain visibility, regulatory compliance documentation and predictive disruption alerts will become competitive differentiators.
The global patent cliff is not a distant threat or promise — it is arriving now. For Indian pharma logistics, the runway is short and the preparation must accelerate.
The winners of the next pharma cycle may not only be drug manufacturers, but also the logistics players capable of moving high-value, temperature-sensitive medicines across continents with precision, compliance, and speed.
.jpg)
.jpg)
